Positive topline Phase IIa data
Positive topline Phase IIa data from the CORIST part 3 trial
Importance of Overall Survival
The importance of Overall Survival in cancer drug development
Gastric SCO-101
Scandion Oncology identifies potentially effective treatment of gastric cancer
Presenting CEO Francois Martelet
Presentation of our new CEO at Scandion Oncology, Francois Martelet
Interim Report Q2 2022
President & CEO Bo Rode Hansen reflects on our achievements and outlook for 2022
CEO 2022
Annual Report 2021